Author

Yanjun Xu

Institution: KeChow Pharma (China)

Observed institution: KeChow Pharma (China)

ORCID: 0009-0006-5524-360X

Observed ORCID: 0009-0006-5524-360X

OpenAlex ID: A5138779706

Efficacy and Safety of Tunlametinib in Adults with Inoperable Neurofibromatosis Type 1–Associated Plexiform Neurofibromas: Phase IIa Trial and Biomarker Research

2026 · Zhichao Wang, Jingxuan Huang, et al. · Clinical Cancer Research · 3

Data from Efficacy and Safety of Tunlametinib in Adults with Inoperable Neurofibromatosis Type 1–Associated Plexiform Neurofibromas: Phase IIa Trial and Biomarker Research

2026 · Zhichao Wang, Jingxuan Huang, et al.

Supplementary Data 1 from Efficacy and Safety of Tunlametinib in Adults with Inoperable Neurofibromatosis Type 1–Associated Plexiform Neurofibromas: Phase IIa Trial and Biomarker Research

2026 · Zhichao Wang, Jingxuan Huang, et al.

Works count: 3

Citation count: 3

H-index: 1

I10-index: